Cargando…

Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant

Infectious diseases remain one of the leading causes of death worldwide. Vaccination is a powerful instrument to avert a variety of those by inducing a pathogen-specific immune response and ensure a long-lasting protection against the respective infection. Nevertheless, due to increasing numbers of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hildebrand, Dagmar, Metz-Zumaran, Camila, Jaschkowitz, Greta, Heeg, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558036/
https://www.ncbi.nlm.nih.gov/pubmed/31214204
http://dx.doi.org/10.3389/fimmu.2019.01279
_version_ 1783425542349914112
author Hildebrand, Dagmar
Metz-Zumaran, Camila
Jaschkowitz, Greta
Heeg, Klaus
author_facet Hildebrand, Dagmar
Metz-Zumaran, Camila
Jaschkowitz, Greta
Heeg, Klaus
author_sort Hildebrand, Dagmar
collection PubMed
description Infectious diseases remain one of the leading causes of death worldwide. Vaccination is a powerful instrument to avert a variety of those by inducing a pathogen-specific immune response and ensure a long-lasting protection against the respective infection. Nevertheless, due to increasing numbers of immunocompromised patients and emergence of more aggressive pathogens existing vaccination techniques are limited. In our study we investigated a new strategy to strengthen vaccine adjuvant in order to increase immunity against infectious diseases. The strategy is based on an amplification of Toll-like receptor 4 (TLR4) -induced activation of antigen-presenting cells (APCs) by turning off a powerful endogenous inhibitor of APC-activation. TLR4 signaling induces the release of cytokines that bind autocrine and paracrine to receptors, activating the Janus kinase (JAK) 2/signal transducers and activators of transcription (STAT) 3 cascade. Subsequently, STAT3 induces expression of suppressor of cytokine signaling (SOCS) 1 that terminates the inflammatory response. In the approach, TLR4-adjuvant monophosphoryl lipid A (MPLA)-stimulated monocyte-activation is reinforced and sustained by silencing SOCS1 via lipid nanoparticle-enclosed siRNA (L-siRNA). L-siRNA is transported into primary cells without any toxic side effects and protected from early degradation. Through lipid core-embedded functional groups the lipid particle escapes from endosomes and releases the siRNA when translocated into the cytoplasm. SOCS1 is potently silenced, and SOCS1-mediated termination of NFκB signaling is abrogated. Consequently, the MPLA-stimulated activation of APCs, monitored by release of pro-inflammatory cytokines such as IL-6, TNFα, and IL-1β, upregulation of MHC class II molecules and costimulatory CD80/CD86 is strongly enhanced and prolonged. SOCS1-silenced APCs, pulsed with liposomal tetanus light chain toxin (TeTxLC) antigen, activate autologous T cells much more intensively than SOCS1-expressing cells. Importantly, expansion of cocultured CD4(+) as well as CD8(+) T cells is remarkably enhanced. Furthermore, our results point toward a broad T helper cell response as TH1 typical as well as TH2 characteristic cytokines are elevated. Taken together, this study in the human system comprises a translational potential to develop more effective vaccines against infectious diseases by inhibition of the endogenous negative-feedback loop in APCs.
format Online
Article
Text
id pubmed-6558036
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65580362019-06-18 Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant Hildebrand, Dagmar Metz-Zumaran, Camila Jaschkowitz, Greta Heeg, Klaus Front Immunol Immunology Infectious diseases remain one of the leading causes of death worldwide. Vaccination is a powerful instrument to avert a variety of those by inducing a pathogen-specific immune response and ensure a long-lasting protection against the respective infection. Nevertheless, due to increasing numbers of immunocompromised patients and emergence of more aggressive pathogens existing vaccination techniques are limited. In our study we investigated a new strategy to strengthen vaccine adjuvant in order to increase immunity against infectious diseases. The strategy is based on an amplification of Toll-like receptor 4 (TLR4) -induced activation of antigen-presenting cells (APCs) by turning off a powerful endogenous inhibitor of APC-activation. TLR4 signaling induces the release of cytokines that bind autocrine and paracrine to receptors, activating the Janus kinase (JAK) 2/signal transducers and activators of transcription (STAT) 3 cascade. Subsequently, STAT3 induces expression of suppressor of cytokine signaling (SOCS) 1 that terminates the inflammatory response. In the approach, TLR4-adjuvant monophosphoryl lipid A (MPLA)-stimulated monocyte-activation is reinforced and sustained by silencing SOCS1 via lipid nanoparticle-enclosed siRNA (L-siRNA). L-siRNA is transported into primary cells without any toxic side effects and protected from early degradation. Through lipid core-embedded functional groups the lipid particle escapes from endosomes and releases the siRNA when translocated into the cytoplasm. SOCS1 is potently silenced, and SOCS1-mediated termination of NFκB signaling is abrogated. Consequently, the MPLA-stimulated activation of APCs, monitored by release of pro-inflammatory cytokines such as IL-6, TNFα, and IL-1β, upregulation of MHC class II molecules and costimulatory CD80/CD86 is strongly enhanced and prolonged. SOCS1-silenced APCs, pulsed with liposomal tetanus light chain toxin (TeTxLC) antigen, activate autologous T cells much more intensively than SOCS1-expressing cells. Importantly, expansion of cocultured CD4(+) as well as CD8(+) T cells is remarkably enhanced. Furthermore, our results point toward a broad T helper cell response as TH1 typical as well as TH2 characteristic cytokines are elevated. Taken together, this study in the human system comprises a translational potential to develop more effective vaccines against infectious diseases by inhibition of the endogenous negative-feedback loop in APCs. Frontiers Media S.A. 2019-06-04 /pmc/articles/PMC6558036/ /pubmed/31214204 http://dx.doi.org/10.3389/fimmu.2019.01279 Text en Copyright © 2019 Hildebrand, Metz-Zumaran, Jaschkowitz and Heeg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hildebrand, Dagmar
Metz-Zumaran, Camila
Jaschkowitz, Greta
Heeg, Klaus
Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
title Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
title_full Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
title_fullStr Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
title_full_unstemmed Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
title_short Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
title_sort silencing socs1 via liposome-packed sirna sustains tlr4-ligand adjuvant
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558036/
https://www.ncbi.nlm.nih.gov/pubmed/31214204
http://dx.doi.org/10.3389/fimmu.2019.01279
work_keys_str_mv AT hildebranddagmar silencingsocs1vialiposomepackedsirnasustainstlr4ligandadjuvant
AT metzzumarancamila silencingsocs1vialiposomepackedsirnasustainstlr4ligandadjuvant
AT jaschkowitzgreta silencingsocs1vialiposomepackedsirnasustainstlr4ligandadjuvant
AT heegklaus silencingsocs1vialiposomepackedsirnasustainstlr4ligandadjuvant